BioMimetic Pharmaceuticals, Inc.
Approvable recommendation issued from FDA panel for GEM 21S
Published in FDA Law Weekly, August 12th, 2004
GEM 21S is being developed for the treatment of bone defects of the jaw in patients with advanced periodontal and periodontal-related diseases requiring surgical treatment. GEM 21S is a combination of a synthetic bone matrix combined with a tissue growth factor.
"We are extremely pleased that the FDA Advisory Panel has provided a strong vote of support for the approval of GEM 21S," stated Samuel E. Lynch, DMD, DMSc, chairman and CEO of BioMimetic Pharmaceuticals.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
Source: FDA Law Weekly (2004-08-12)
More Articles from FDA Law Weekly
- Titan, Pharmaceuticals, Inc
Spheramine for Parkinson receives FDA fast track designation - American Pharmaceutical Partners, Inc.
Tobramycin powder launched, marking company's first NDA approval - Atrix Laboratories, Inc.
Tentative approval granted from FDA for Mometasone cream - Barr Pharmaceuticals, Inc.
Response submitted to FDA in support of OTC status for emergency contraceptive - Bioterrorism
Report shows bioterrorism preparedness progress lacking in rural areas - Blood Safety
West Nile prompts rethinking of blood donors - More from this issue of FDA Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
